Syphilis has re-emerged as a public health threat during the 21st century, and updated knowledge of the epidemic and its drivers is needed to halt this worrying development. We present data on the incidence of syphilis in the south Swedish region Skåne from 2007 to 2022 to determine the burden of disease, changes in risk groups, as well as routes for testing. To get a picture of the burden of syphilis, both early (notifiable) syphilis and cases of non-notifiable (late) symptomatic syphilis were included in this register-based study. Mann–Kendall trend analysis (MK) was used to determine statistical significance over time. In all, 584 cases of syphilis were included in the study. The overall syphilis incidence in Skåne increased from 3.1 cases/100000 population in 2007 to 6.3 in 2022 (MK z-stat: 2.57; p = 0.010). The highest increase in absolute numbers was among men who have sex with men (MSM), from eight cases annually in 2007 to 62 in 2022, but also for heterosexually transmitted men and women, with under ten cases yearly from 2007 through 2019 to 22 cases in 2022. We also found that transmission within Sweden was common, indicating that local measures are needed to curb this epidemic.

There is a positive association between bacteraemia with Streptococcus bovis–Streptococcus equinus complex (SBSEC) and colorectal cancer (CRC). However, the relationship between the timing of SBSEC bacteraemia and CRC is not well-established. Associations with other gastrointestinal cancers have also been suggested. Using national registries, we retrospectively examined the incidence of CRC and other gastrointestinal cancers after SBSEC-bacteraemia in Sweden 2010–2019, and analysed the timing, characteristics, and prognosis of diagnosed CRC. Individuals with SBSEC-bacteraemia were matched to randomly selected controls from the general population at a 1:10 ratio. Cox-regression determined CRC hazard ratios (HR). In total, 908 individuals with SBSEC-bacteraemia were identified and 9,080 controls, of whom 75/908 (8.3%) and 168/9080 (1.9%) respectively had previously diagnosed CRC (p < 0.01). During follow-up of individuals without previous CRC, CRC was diagnosed in 45/833 (5.4%) individuals with SBSEC and 114/8912 (1.3%) controls (p < 0.01). The HR of CRC diagnosis for SBSEC was 10.3 (95% CI 6.7–15.8) overall and 19.8 (95% CI 11.1–35.3) during the first year of follow-up. In conclusion, there was an increased incidence of CRC, and most were diagnosed within the first year. Neither the tumour location, −stage, or -grade of diagnosed CRC nor the rates of other gastrointestinal cancers differed significantly.

Our study assessed the link between gastrointestinal (GI) infections in England and the Eat Out to Help Out scheme (EOHO), a government subsidy created to encourage people to eat out during COVID-19 pandemic (03–30 August 2020). We studied national laboratory data between January 2015 and December 2020. We used time series change point analysis to see if there were shifts in reported cases of specific GI infections (Campylobacter spp., Escherichia coli O157, and non-typhoidal Salmonella spp.) associated with the timing of the scheme. Our analysis uniquely applied the Pruned Exact Linear Time method, with generalized linear models to a national dataset of GI infections. This revealed increases in cases closely aligned to the timing of the easing of COVID-19 restrictions, prior to the introduction of the EOHO scheme. Our study showed the scheme had no measurable impact, as there was no significant change on reported cases. Substantial reductions in cases after the first lockdown, followed by an increase as restrictions were phased out, show the wider impact of COVID-19 control measures, for example, public information campaigns aimed at improving hand-hygiene. These findings highlight the complicated interactions between COVID-19 control measures, the public’s behaviour, and the spread of GI infections.

This study examined whether coronavirus disease 2019 (COVID-19) infection experience enhances preventive behaviour (i.e., hand disinfection and mask-wearing), with risk perception acting as a mediating factor. The study included participants aged ≥18 years residing in Japan, enrolled in a 30-wave cohort study conducted from January 2020 to March 2024. Using propensity score matching, 135 pairs of participants with and without infection were extracted, adjusting for dread and unknown risk perception, preventive behaviours, sociopsychological variables, and individual attributes. Comparisons of risk perception and preventive behaviour were made between groups post-infection experience, and mediation analysis was conducted to test whether risk perception mediated the effect of infection experience on preventive behaviour. Following the infection experience, participants in the infection group reported significantly higher scores for one item of unknown risk perception and a greater proportion of mask-wearing. The indirect effect of infection experience on mask-wearing, mediated by the unknown risk perception item, was significant. COVID-19 infection experience increased perceptions of unknowable exposure, which in turn promoted mask-wearing behaviour. Incorporating insights from personal infection experiences into public health messaging may enhance risk perception and promote preventive behaviour among non-infected individuals, offering a novel approach to infection control at the population level.

Effectiveness of nirsevimab against respiratory syncytial virus (RSV) hospitalization during the 2024/2025 season in Spain was estimated using a test-negative design (TND) and hospital-based respiratory infections surveillance data. Children born between 1 April 2024 and 31 March 2025 and hospitalized with severe respiratory infection between the start of the 2024 immunization campaign (regionally variable, between 16 September and 1 October 2024) and 31 March 2025 were systematically RT-PCR RSV-tested within 10 days of symptom onset and classified as cases if positive or controls if negative. Nirsevimab effectiveness ((1 − odds ratio) × 100) was estimated using logistic regression, adjusted for admission week, age, sex, high-risk factors, and regional RSV hospitalization rate. We included 199 cases (68.8% immunized) and 360 controls (86.4% immunized). Overall effectiveness was 65.5% (95% confidence interval: 45.2 to 78.3). Effectiveness was similar among infants born before and after the campaign start (63.6% vs. 70.4%, respectively). We found an unexpected early decrease in effectiveness with increasing time since immunization and age, albeit with wide confidence intervals for some groups. Strong age–period–cohort effects and potential sources of bias were identified, highlighting the need to further explore methodological challenges of implementing the TND in the dynamic population of newborns.

Despite efforts by the Volta River Authority (VRA) to provide services for schistosomiasis control in communities along Ghana’s Volta Basin, high rates of transmission and re-infection persist in the region. To strengthen intervention effectiveness, the VRA partnered with the University of Health and Allied Sciences to conduct implementation research aimed at developing context-specific, evidence-based quality improvement strategies. This mixed-method study evaluates the reach, effectiveness, adoption, implementation, and maintenance of the VRA’s quality improvement intervention for their mass drug administration (MDA) for schistosomiasis. Baseline and endline surveys were analysed using STATA and qualitative data from in-depth interviews (IDIs) and focus group discussions (FGDs) were coded and analysed thematically using Taguette. Urogenital schistosomiasis prevalence decreased by 87.83% in Shai Osudoku, 88.98% in South Tongu, and 90.96% in Asuogyaman after the intervention. The findings revealed high training levels among district health management staff and community drug distributors, high health worker satisfaction with the training, and positive community reception of the intervention. However, praziquantel side effects and related opportunity costs may have posed a barrier to drug uptake. Moreover, re-infection remains a challenge, which could be attributed to high domestic and economic reliance on the Volta River.

The activity of respiratory viruses (RVs) displays large variability in tropical regions, posing challenges for public health response strategies. Data from most RVs in south-eastern Mexico remain limited, particularly in the Yucatan Peninsula, the largest tourism hub in the country. This retrospective study analyses the regional epidemiology of RVs in Merida, the largest city in the region, using laboratory test data from a local hospital (January 2018–April 2024). Test results of 143292 RVs were collected, including 121976 for SARS-CoV-2, 19355 for influenza A and B viruses, and 1961 for 17 distinct RVs. We found that non-SARS-CoV-2 RVs circulated year-round, with higher activity in autumn and spring, while SARS-CoV-2 peaked in summer and winter. Influenza A virus, respiratory syncytial virus, and influenza B virus reached their highest activity in autumn, earlier than in other regions of Mexico. Human metapneumovirus peaked during autumn-winter. Rhinovirus/enterovirus and parainfluenza showed year-round activity, with peaks in autumn and spring. Other coronaviruses were more frequent during winter-spring. In post-pandemic years (2022–2023), adenovirus outbreaks emerged, as well as an increased prevalence of non-SARS-CoV-2 RV co-infections. This study highlights the need for region-specific public health strategies, including optimized vaccination schedules, such as for influenza A virus, and enhanced diagnostic surveillance.

This cross-sectional study investigated how care home size influences COVID-19 transmission dynamics, focusing on outbreaks in England during the second wave of COVID-19 (Wave 2; December 2020 to March 2021) and the Omicron wave (December 2021 to February 2022). Using data from the UK Health Security Agency and the Care Quality Commission, positive SARS-CoV-2 test results were matched to care home registration and occupancy data, examining outbreak trajectories in homes of varying sizes and resident age groups. The study included over 90,000 positive cases across the two waves. Small care homes (SCHs, with 10 or fewer beds), predominantly housing younger adults, showed significantly higher early positivity rates: 42% of residents were positive at outbreak detection, rising to 61% by day 7. In contrast, larger homes had early positivity rates of only 3–6%. These findings suggest that SCHs, often designed for communal living, facilitate rapid within-home transmission similar to household settings. The study concludes that outbreak control strategies in SCHs should differ from those in larger care homes, emphasizing proportionate, individualized approaches that consider resident vulnerability and minimize disruption to social support systems. These results have broader implications for managing future infectious disease outbreaks and support the development of tailored guidance based on care home size and resident demographics.

We aimed to describe the evolution of gonorrhea infection and its antimicrobial resistance patterns in the Prairie provinces compared to Canada between 1980 and 2022. Data was collected from publicly available sexually transmitted infection reports in Canada, Alberta, Saskatchewan, and Manitoba. We extracted the number and rates of gonorrhea cases; percentage of cases by sex, age, ethnicity, sexual orientation; and data on cases diagnosed by culture and antimicrobial resistance. Descriptive statistics and age–period–cohort effect analysis were used. Gonorrhea cases in Canada rose from 32.4 per 100 000 in 1992 to 92.3 in 2022. In 2020, 36.9% of gonorrhea cases in Canada were females, compared to 42.8% in Alberta, 55.3% in Saskatchewan and 56% in Manitoba. People aged ≥30 years represented 22.5% of cases in 1980, and 54.1% in 2022. By 2022, the proportion of Canadian cases detected by culture declined to less than 10%, and azithromycin resistance of N. gonorrhoeae isolates was 8.1%. Alberta, Manitoba, and Saskatchewan reported higher rates of gonorrhea compared to Canada, with a higher proportion of female cases in Manitoba and Saskatchewan. Rising antimicrobial resistance rates and decreased culture testing present significant concerns for gonorrhea control and surveillance.

We estimated the vaccine effectiveness (VE) of second monovalent and bivalent booster vaccines containing Omicron BA.1 or BA.4/BA.5 and the protection conferred by natural immunity against SARS-CoV-2 infection in Luxembourg. We conducted a test-negative case–control study among residents aged 60 years or older by integrating national socio-demographic, COVID-19 vaccination, and testing data, achieving full population coverage. Using conditional logistic regression, we estimated absolute and relative VE of monovalent and bivalent boosters and natural immunity from prior infection. Our analysis included 5,390 test-positive cases and 11,048 test-negative controls matched by week of testing between September 2022 and April 2023. Absolute VE for monovalent and bivalent boosters decreased from 64.8% and 66.6% in the first month to 1.5% and 16.5% after 5–6 months, respectively. The bivalent was superior to the monovalent booster only in individuals without natural immunity (relative VE 25.7%, 95% confidence interval 11.4%; 37.7%). Natural immunity lasted longer than vaccine-induced immunity with 80.7% protected at 4–8 months and 44.9% at 15–25 months post-infection. Both second booster vaccines provided temporary protection against SARS-CoV-2 infection; bivalent boosters offered a slight benefit over monovalent boosters. Natural immunity appears to confer longer-lasting protection.

Nationwide screening for parvovirus B19 among blood donors in Hungary has been conducted since 2019. Although B19 is primarily transmitted via the respiratory route, transfusion-related transmission also occurs. This study investigated the impact of COVID-19–related restrictions on B19 incidence. Between January 1 2019 and December 31 2024, a total of 2,043,119 blood donations were screened for B19 DNA using PCR, and the study period was divided into six epidemiological phases.

During the pre-restriction period (Phase I), B19 incidence was relatively low (0.87/10,000 donations). Following the introduction of COVID-19 restrictions (Phase II), highly viremic donations were not detected. Incidence gradually returned in Phase III (0.22/10000) and increased in Phase IV (1.96/10000), suggesting a minor outbreak. A marked surge in December 2023 (23.03/10000) initiated a nationwide epidemic, peaking in March–April 2024 (46.01/10000), before declining by August (Phase VI; 0.54/10000).

COVID-19 restrictions substantially reduced B19 transmission and may have led to increased population susceptibility. This likely contributed to the unusually intense B19 epidemic observed in 2024, which was considerably more severe than contemporaneous outbreaks reported in other countries.